By making key signaling molecules called β-arrestins into druggable targets, scientists crack long-standing challenge (opens in new tab)

To function normally, nearly every cell in the human body relies on G-protein-coupled receptors (GPCRs) to receive and send signals. That's why GPCRs are targeted by roughly one-third of all FDA-approved drugs.